Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Sernova Corp

Healthcare CA SVA

0.155CAD
-0.005(3.12%)

Last update at 2026-06-04T19:44:00Z

Day Range

0.150.16
LowHigh

52 Week Range

0.120.23
LowHigh

Fundamentals

  • Previous Close 0.16
  • Market Cap62.59M
  • Volume113954
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.12429M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Income before tax -15.83566M -32.18514M -39.62654M -24.42054M -6.96554M
Minority interest - - - - -
Net income -15.74347M -32.19214M -38.99752M -24.53854M -7.00676M
Selling general administrative 7.50M 8.97M 8.46M 7.83M 2.29M
Selling and marketing expenses - - 8.42M - -
Gross profit -0.34259M - -0.44555M - -
Reconciled depreciation 0.34M 0.54M 0.45M 0.44M 0.27M
Ebit -15.08084M -31.66374M -40.50159M -24.17648M -6.86595M
Ebitda -14.73825M -31.25321M -40.19310M -23.73648M -6.59875M
Depreciation and amortization 0.34M 0.41M 0.31M 0.44M 0.27M
Non operating income net other - - - - -
Operating income -15.12465M -31.83810M -41.13062M -24.17648M -6.86595M
Other operating expenses 15.12M 31.84M 41.13M 24.75M 6.94M
Interest expense 0.75M 0.59M 0.03M 0.12M 0.06M
Tax provision 0.00943M 0.00700M 0.00000M - -
Interest income 0.03M 0.54M 1.50M 0.33M 0.02M
Net interest income -0.72918M -0.19847M 1.47M 0.46M 0.01M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.09219M 0.00700M -0.62902M 0.12M 0.04M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 14.78M 31.84M 41.13M 24.75M 6.94M
Cost of revenue 0.34M - 0.45M - -
Total other income expense net -0.71101M -0.34704M 1.50M -0.24406M -0.09958M
Discontinued operations - - - - -
Net income from continuing ops -15.74347M -32.19214M -38.99752M -24.42054M -6.96554M
Net income applicable to common shares -15.74347M -32.19214M -38.99752M -24.42054M -6.96554M
Preferred stock and other adjustments - - - - -
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Total assets 0.76M 7.53M 22.11M 52.48M 29.82M
Intangible assets - - 0.00032M 0.52M 0.72M
Earning assets - - - - -
Other current assets 0.14M 0.16M 0.16M 0.17M -
Total liab 25.84M 20.48M 9.59M 4.88M 1.75M
Total stockholder equity -25.07683M -12.95661M 12.51M 47.61M 28.07M
Deferred long term liab - - - - -
Other current liab 8.56M - 2.61M 0.99M 0.98M
Common stock 118.70M - 110.99M 110.99M 74.01M
Capital stock 118.70M 116.68M 110.99M 110.99M 74.01M
Retained earnings -166.10261M -150.35914M -118.16701M -79.16949M -54.74895M
Other liab - - - - -
Good will - - 0.32M - -
Other assets 0.22M - 0.00000M 0.22M 0.21M
Cash 0.27M 6.01M 8.72M 3.78M 27.87M
Cash and equivalents - - - - -
Total current liabilities 24.80M 20.02M 9.59M 4.74M 1.48M
Current deferred revenue - - - - -
Net debt 17.02M - -8.58571M -3.50007M -27.48084M
Short term debt 16.24M - 0.14M 0.14M 0.12M
Short long term debt - - - - -
Short long term debt total 17.28M - 0.14M 0.28M 0.39M
Other stockholder equity 21.79M - 19.69M 15.79M 8.81M
Property plant equipment 0.02M - - 0.65M 0.56M
Total current assets 0.52M 6.47M 21.02M 51.09M 28.33M
Long term investments - - - - -
Net tangible assets - - - 47.09M 27.35M
Short term investments - 0.00000M 11.08M 46.00M -
Net receivables 0.12M - 1.05M 1.15M 0.45M
Long term debt 1.04M - - - 0.00000M
Inventory - - - - -
Accounts payable 5.16M 17.24M 6.85M 3.61M 0.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.54M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.22M - 0.26M 0.22M 0.60M
Deferred long term asset charges - - - - -
Non current assets total 0.24M 1.06M 1.08M 1.39M 1.49M
Capital lease obligations 0.00000M 0.57M 0.14M 0.28M 0.39M
Long term debt total 1.04M - - 0.14M 0.28M
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Investments 0.00000M 11.12M 34.78M -46.34131M -0.22878M
Change to liabilities - - - 3.31M 0.46M
Total cashflows from investing activities 0.02M 11.12M 34.78M -46.34131M -0.22878M
Net borrowings 4.82M -0.16923M -0.17193M -0.16856M -0.02800M
Total cash from financing activities 5.14M 5.07M 0.50M 36.66M 31.00M
Change to operating activities - - - -0.16381M 0.14M
Net income -15.74347M -32.19214M -38.99752M -24.42054M -6.96554M
Change in cash -5.74727M -2.70956M 4.95M -24.09814M 23.92M
Begin period cash flow 6.01M 8.72M 3.78M 27.87M 3.95M
End period cash flow 0.27M 6.01M 8.72M 3.78M 27.87M
Total cash from operating activities -10.90797M -18.89631M -30.33912M -14.42140M -6.84374M
Issuance of capital stock 0.25M 4.96M 0.00000M 20.28M 21.13M
Depreciation 0.34M 0.54M 0.45M 0.44M 0.27M
Other cashflows from investing activities 0.02M 0.04M -0.03530M -46.01231M -0.21155M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.18M 0.56M 0.23M -0.19504M -0.08980M
Sale purchase of stock 0.25M 4.98M 0.00000M 36.51M 29.90M
Other cashflows from financing activities -0.04793M 0.28M 0.68M 16.55M 9.90M
Change to netincome - - - 6.61M -0.66296M
Capital expenditures 0.00000M 0.00000M 0.10M 0.33M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.74M 11.16M 4.99M 2.95M 0.52M
Stock based compensation 2.30M 1.75M 3.90M 7.45M 0.22M
Other non cash items 0.52M -0.15048M -0.67634M -0.83857M -0.88136M
Free cash flow -10.90797M -18.89631M -30.43838M -14.75040M -6.86097M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SVA
Sernova Corp		 -0.005 3.12% 0.15 - - 65.86 24.15 36.69 -11.2729
EPRX
Eupraxia Pharmaceuticals Inc		 0.16 1.80% 9.03 - - - 8.45 -3.8823
FRX
Fennec Pharmaceuticals Inc		 -1.04 7.56% 12.72 - 21.01 6.95 6.35 4.25 20.27
MSCL
Satellos Bioscience Inc.		 -0.01 0.12% 8.30 - - - 5.85 6.47
HBP
Helix BioPharma Corp.		 -0.01 0.63% 1.57 - 3.87 4263.36 9.74 4422.35 -6.3589

Reports Covered

Stock Research & News

View All

Profile

Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is based in Mississauga, Canada.

Sernova Corp

RPO Central Parkway, Mississauga, ON, Canada, L5A 4H2

Key Executives

Name Title Year Born
Mr. Frank A. Holler MBA Exec. Chairman 1957
Dr. Philip M. Toleikis B.A., M.Sc., Ph.D. Pres, CEO & Director NA
Mr. David Swetlow C.A, C.A., CPA Chief Financial Officer NA
Mr. Douglas Maret Chief Science Officer NA
Mr. Christopher Barnes VP of Investor Relations NA
Mr. James T. Parsons CPA-CA, MAcc CFO & Director 1965
Dr. Modestus Obochi M.B.A., Ph.D. Chief Business Officer NA
Dr. Frank Shannon M.D. Vice President of Clinical Development & Regulatory Affairs NA
Mr. Jonathan M. N. Rigby M.B.A., MBA Executive Chairman 1968
Mr. David Burke Vice President of Investor Relations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.